Stoke Therapeutics
Price & Volume
Stats
See moreOpen | $30.23 |
Previous Close | $30.34 |
Day Range | $28.86-$30.45 |
52W Range | $5.35-$38.69 |
Market Cap | $1.6B |
Shares Short | 10M |
Financials
See moreRevenue (12 Mos) | $205.6M |
Revenue Growth (YoY) | 117.2% |
Gross Profit (12 Mos) | $205.6M |
Diluted EPS | $0.68 |
News
See moreYahoo Finance • 7 days ago
A Look at Biogen (BIIB) Valuation Following New Dravet Syndrome Study Results
Yahoo Finance • 9 days ago
Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
Yahoo Finance • 9 days ago
Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
Yahoo Finance • 20 days ago
Implied JSMD Analyst Target Price: $92
About
CEO | Mr. Ian F. Smith A.C.A., C.P.A. |
Address | 45 Wiggins Avenue, Bedford, MA, United States, 01730 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 128 |
